In vivo, Ex-4 has been demonstrated to inhibit prostate cancer cell growth by activating GLP-1R, reducing s-phase kinase-associated protein-2 (SKP2) gene expression, subsequently increasing p27Kip1 (p27) protein levels, and inducing tumor cell cycle arrest [67]. This evidence concerns the gene CDKN1B and prostate cancer.